Neumora Therapeutics (NMRA) Net Income towards Common Stockholders (2022 - 2026)

Neumora Therapeutics has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$53.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 21.38% year-over-year to -$53.5 million; the trailing twelve-month figure through Mar 2026 stood at -$222.4 million (up 13.82% YoY), and the FY2025 full-year result was -$236.9 million, up 2.81% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$53.5 million, up from -$59.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$28.4 million in Q4 2022, with the low at -$108.5 million in Q4 2023.
• Average Net Income towards Common Stockholders over 5 years is -$55.2 million, with a median of -$53.7 million recorded in 2024.
• Year-over-year, Net Income towards Common Stockholders plunged 281.47% in 2023 and soared 45.77% in 2024.
• Tracing NMRA's Net Income towards Common Stockholders over 5 years: stood at -$28.4 million in 2022, then sank by 281.47% to -$108.5 million in 2023, then soared by 45.77% to -$58.8 million in 2024, then fell by 1.07% to -$59.4 million in 2025, then gained by 10.08% to -$53.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$53.5 million (Q1 2026), -$59.4 million (Q4 2025), and -$56.8 million (Q3 2025), per Business Quant data.

Peer Comparison